HAMID TAHERI
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease
- Where
- Reston, VA
- NPI
- 1295773679
- Received
- $504,155 in 1,468 records, 2019 to 2025 ($501,448 general, $2,706 research)
- As principal investigator
- $4,351,144 of research payments to others in 118 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 194 | $78,856 |
| 2025 | Research payment | 1 | $2,706 |
| 2024 | General payment | 209 | $103,513 |
| 2023 | General payment | 162 | $44,443 |
| 2022 | General payment | 227 | $71,981 |
| 2021 | General payment | 247 | $58,688 |
| 2020 | General payment | 170 | $62,704 |
| 2019 | General payment | 258 | $81,261 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 175 | $425,760 |
| Food and Beverage | 1,199 | $42,821 |
| Consulting Fee | 8 | $16,438 |
| Travel and Lodging | 73 | $16,217 |
| Research payment | 1 | $2,706 |
| Education | 12 | $211 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | BridgeBio Pharma, Inc. | $22 | Food and Beverage | In-kind items and services | Attruby Drug, Cardiomyopathy | 2025 | |
| 2025-12-24 | Novartis Pharmaceuticals Corporation | $15 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-12-19 | Recor Medical Inc | $145 | Food and Beverage | Cash or cash equivalent | Paradise Ultrasound Renal Denervation System Device, Devices | 2025 | |
| 2025-12-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-12-16 | scPharmaceuticals Inc. | $122 | Food and Beverage | In-kind items and services | FUROSCIX Drug, Cardiology | 2025 | |
| 2025-12-12 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | 2025 | |
| 2025-12-11 | Recor Medical Inc | $28 | Food and Beverage | Cash or cash equivalent | Paradise Ultrasound Renal Denervation System Device, Devices | 2025 | |
| 2025-12-08 | Amgen Inc. | $2,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-12-06 | Novo Nordisk Inc | $30 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-12-04 | Novo Nordisk Inc | $121 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-12-03 | Amgen Inc. | $124 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-12-03 | Bayer Healthcare Pharmaceuticals Inc. | $25 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-11-25 | BridgeBio Pharma, Inc. | $17 | Food and Beverage | In-kind items and services | Attruby Drug, Cardiomyopathy | 2025 | |
| 2025-11-20 | Novo Nordisk Inc | $5,102 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-11-20 | Novo Nordisk Inc | $97 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-20 | Merck Sharp & Dohme LLC | $35 | Food and Beverage | In-kind items and services | Drug, CARDIOVASCULAR | 2025 | |
| 2025-11-19 | Novo Nordisk Inc | $5,102 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-11-19 | Novo Nordisk Inc | $124 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-11-18 | AstraZeneca Pharmaceuticals LP | $120 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-13 | Recor Medical Inc | $146 | Food and Beverage | Cash or cash equivalent | Paradise Ultrasound Renal Denervation System Device, Devices | 2025 | |
| 2025-11-13 | ABIOMED | $76 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-13 | E.R. Squibb & Sons, L.L.C. | $16 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2025 | |
| 2025-11-12 | Lilly USA, LLC | $1,430 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, Diabetes | 2025 | |
| 2025-11-12 | Bayer Healthcare Pharmaceuticals Inc. | $30 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-11-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-11-07 | Boston Scientific Corporation | $27 | Food and Beverage | In-kind items and services | WATCHMAN Access System Device, WATCHMAN_IC | 2025 | |
| 2025-11-06 | scPharmaceuticals Inc. | $16 | Food and Beverage | In-kind items and services | FUROSCIX Drug, Cardiology | 2025 | |
| 2025-11-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | $103 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-11-05 | Esperion Therapeutics, Inc. | $28 | Food and Beverage | In-kind items and services | NEXLETOL Drug, ANTILIPEMIC AGENTS | 2025 | |
| 2025-11-05 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-11-01 | Novo Nordisk Inc | $5,102 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-11-01 | Novo Nordisk Inc | $33 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-10-31 | scPharmaceuticals Inc. | $19 | Food and Beverage | In-kind items and services | FUROSCIX Drug, Cardiology | 2025 | |
| 2025-10-30 | Recor Medical Inc | $25 | Food and Beverage | Cash or cash equivalent | Paradise Ultrasound Renal Denervation System Device, Devices | 2025 | |
| 2025-10-29 | Amgen Inc. | $23 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-10-28 | Esperion Therapeutics, Inc. | $18 | Food and Beverage | In-kind items and services | NEXLETOL Drug, ANTILIPEMIC AGENTS | 2025 | |
| 2025-10-23 | Novo Nordisk Inc | $3,532 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-10-23 | Novo Nordisk Inc | $122 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-10-23 | scPharmaceuticals Inc. | $7 | Food and Beverage | In-kind items and services | FUROSCIX Drug, Cardiology | 2025 | |
| 2025-10-21 | Novo Nordisk Inc | $5,102 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-10-21 | Novo Nordisk Inc | $106 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-10-17 | Recor Medical Inc | $7 | Food and Beverage | Cash or cash equivalent | Paradise Ultrasound Renal Denervation System Device, Devices | 2025 | |
| 2025-10-16 | Abbott Laboratories | $151 | Food and Beverage | In-kind items and services | ESPRIT Device, Vascular | 2025 | |
| 2025-10-15 | Lilly USA, LLC | $20 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-10-10 | ABIOMED | $19 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-09 | Bayer Healthcare Pharmaceuticals Inc. | $18 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-10-08 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-10-07 | Novo Nordisk Inc | $5,102 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-10-07 | Novo Nordisk Inc | $25 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-10-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,850 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-10-02 | Merck Sharp & Dohme LLC | $19 | Food and Beverage | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | 2025 | |
| 2025-10-01 | Actelion Pharmaceuticals US, Inc. | $24 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2025 | |
| 2025-09-25 | Medtronic, Inc. | $84 | Food and Beverage | In-kind items and services | HAWKONE Device, Directional Atherectomy Devices | 2025 | |
| 2025-09-25 | Philips North America LLC | $47 | Food and Beverage | Cash or cash equivalent | Peripheral Vascular Undivided Device, Medical Device | 2025 | |
| 2025-09-25 | Terumo Medical Corporation | $44 | Food and Beverage | In-kind items and services | ANGIO-SEAL Device, VASCULAR ACCESS | 2025 | |
| 2025-09-25 | W. L. Gore & Associates, Inc. | $30 | Food and Beverage | In-kind items and services | GORE VIABAHN VBX Balloon Expandable Endo Device, Devices | 2025 | |
| 2025-09-25 | Cook Medical LLC | $30 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-09-24 | AstraZeneca Pharmaceuticals LP | $32 | Food and Beverage | In-kind items and services | LOKELMA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-09-23 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-09-23 | CVRx, Inc. | $11 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2025 | |
| 2025-09-23 | CVRx, Inc. | $4 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2025 | |
| 2025-09-19 | E.R. Squibb & Sons, L.L.C. | $21 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2025 | |
| 2025-09-19 | Novartis Pharmaceuticals Corporation | $10 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-09-19 | Novartis Pharmaceuticals Corporation | $3 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-09-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | $117 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-09-17 | Medtronic, Inc. | $107 | Food and Beverage | In-kind items and services | LINQ II Device, Cardiac Diagnostics and Monitoring | 2025 | |
| 2025-09-17 | Merck Sharp & Dohme LLC | $31 | Food and Beverage | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | 2025 | |
| 2025-09-16 | Medtronic, Inc. | $58 | Food and Beverage | In-kind items and services | LINQ II Device, Cardiac Diagnostics and Monitoring | 2025 | |
| 2025-09-16 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-09-11 | CVRx, Inc. | $14 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2025 | |
| 2025-09-10 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-04 | scPharmaceuticals Inc. | $22 | Food and Beverage | In-kind items and services | FUROSCIX Drug, Cardiology | 2025 | |
| 2025-09-04 | BridgeBio Pharma, Inc. | $16 | Food and Beverage | In-kind items and services | Attruby Drug, Cardiomyopathy | 2025 | |
| 2025-09-03 | Bayer Healthcare Pharmaceuticals Inc. | $16 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-28 | Kestra Medical Technology Services, Inc. | $24 | Food and Beverage | Cash or cash equivalent | Assure WCD Device, Cardiology/Vascular Diseases | 2025 | |
| 2025-08-28 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $11 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2025 | |
| 2025-08-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-08-27 | Novartis Pharmaceuticals Corporation | $5 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-08-27 | Novartis Pharmaceuticals Corporation | $1 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-08-22 | E.R. Squibb & Sons, L.L.C. | $19 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2025 | |
| 2025-08-22 | scPharmaceuticals Inc. | $4 | Food and Beverage | In-kind items and services | FUROSCIX Drug, Cardiology | 2025 | |
| 2025-08-22 | E.R. Squibb & Sons, L.L.C. | $1 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2025 | |
| 2025-08-21 | BridgeBio Pharma, Inc. | $24 | Food and Beverage | In-kind items and services | Attruby Drug, Cardiomyopathy | 2025 | |
| 2025-08-21 | E.R. Squibb & Sons, L.L.C. | $18 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2025 | |
| 2025-08-19 | Lilly USA, LLC | $124 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-08-15 | Actelion Pharmaceuticals US, Inc. | $22 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2025 | |
| 2025-08-13 | Philips North America LLC | $27 | Food and Beverage | Cash or cash equivalent | Business Operations Device, Medical Device | 2025 | |
| 2025-08-12 | scPharmaceuticals Inc. | $11 | Food and Beverage | In-kind items and services | FUROSCIX Drug, Cardiology | 2025 | |
| 2025-08-07 | Bayer Healthcare Pharmaceuticals Inc. | $18 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-08-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-08-07 | E.R. Squibb & Sons, L.L.C. | $1 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2025 | |
| 2025-07-31 | Novo Nordisk Inc | $26 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-07-30 | Novo Nordisk Inc | $5,102 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-07-30 | Novo Nordisk Inc | $124 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-07-30 | E.R. Squibb & Sons, L.L.C. | $11 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2025 | |
| 2025-07-30 | E.R. Squibb & Sons, L.L.C. | $3 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2025 | |
| 2025-07-29 | BridgeBio Pharma, Inc. | $12 | Food and Beverage | In-kind items and services | Attruby Drug, Cardiomyopathy | 2025 | |
| 2025-07-25 | Novo Nordisk Inc | $24 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-07-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-07-23 | Novartis Pharmaceuticals Corporation | $7 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-07-23 | Novartis Pharmaceuticals Corporation | $1 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-07-18 | scPharmaceuticals Inc. | $27 | Food and Beverage | In-kind items and services | FUROSCIX Drug, Cardiology | 2025 | |
| 2025-07-17 | Recor Medical Inc | $6 | Food and Beverage | Cash or cash equivalent | Paradise Ultrasound Renal Denervation System Device, Devices | 2025 | |
| 2025-07-16 | Amgen Inc. | $23 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-07-15 | BridgeBio Pharma, Inc. | $144 | Food and Beverage | In-kind items and services | Attruby Drug, Cardiomyopathy | 2025 | |
| 2025-07-14 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $2 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2025 | |
| 2025-07-11 | Esperion Therapeutics, Inc. | $23 | Food and Beverage | In-kind items and services | NEXLETOL Drug, ANTILIPEMIC AGENTS | 2025 | |
| 2025-07-10 | Novartis Pharmaceuticals Corporation | $28 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-07-10 | Recor Medical Inc | $4 | Food and Beverage | Cash or cash equivalent | Paradise Ultrasound Renal Denervation System Device, Devices | 2025 | |
| 2025-07-09 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-07-01 | BridgeBio Pharma, Inc. | $10 | Food and Beverage | In-kind items and services | Attruby Drug, Cardiomyopathy | 2025 | |
| 2025-06-26 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $20 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2025 | |
| 2025-06-25 | Novo Nordisk Inc | $1,167 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-06-20 | Merck Sharp & Dohme LLC | $20 | Food and Beverage | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | 2025 | |
| 2025-06-18 | Ionis Pharmaceuticals, Inc. | $122 | Food and Beverage | In-kind items and services | TRYNGOLZA Drug, CARDIOLOGY | 2025 | |
| 2025-06-17 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-06-13 | Lilly USA, LLC | $20 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-06-13 | Novartis Pharmaceuticals Corporation | $6 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-06-12 | Actelion Pharmaceuticals US, Inc. | $77 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2025 | |
| 2025-06-10 | Esperion Therapeutics, Inc. | $12 | Food and Beverage | In-kind items and services | NEXLETOL Drug, ANTILIPEMIC AGENTS | 2025 | |
| 2025-06-06 | scPharmaceuticals Inc. | $23 | Food and Beverage | In-kind items and services | FUROSCIX Drug, Cardiology | 2025 | |
| 2025-06-05 | Baxter Healthcare | $58 | Food and Beverage | In-kind items and services | Hillrom - Carnation Ambulatory Monitor Device, Cardiac Arrhythmia Monitoring | 2025 | |
| 2025-06-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-06-03 | CVRx, Inc. | $20 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2025 | |
| 2025-05-30 | E.R. Squibb & Sons, L.L.C. | $19 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2025 | |
| 2025-05-28 | Recor Medical Inc | $102 | Food and Beverage | Cash or cash equivalent | Paradise Ultrasound Renal Denervation System Device, Devices | 2025 | |
| 2025-05-28 | PFIZER INC. | $18 | Food and Beverage | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | 2025 | |
| 2025-05-28 | Recor Medical Inc | $8 | Food and Beverage | Cash or cash equivalent | Paradise Ultrasound Renal Denervation System Device, Devices | 2025 | |
| 2025-05-28 | Novartis Pharmaceuticals Corporation | $5 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-05-23 | Chiesi USA, Inc. | $14 | Food and Beverage | Cash or cash equivalent | KENGREAL Drug, CARDIOVASCULAR | 2025 | |
| 2025-05-22 | Novo Nordisk Inc | $34 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-05-21 | Esperion Therapeutics, Inc. | $5 | Food and Beverage | In-kind items and services | NEXLETOL Drug, ANTILIPEMIC AGENTS | 2025 | |
| 2025-05-20 | Novo Nordisk Inc | $5,102 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-05-20 | Novo Nordisk Inc | $119 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-05-16 | Lilly USA, LLC | $30 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-05-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-05-13 | Amgen Inc. | $2,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiovascular | 2025 | |
| 2025-05-13 | Amgen Inc. | $467 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiovascular | 2025 | |
| 2025-05-09 | Kestra Medical Technology Services, Inc. | $23 | Food and Beverage | Cash or cash equivalent | Assure WCD Device, Cardiology/Vascular Diseases | 2025 | |
| 2025-05-09 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-05-08 | Amgen Inc. | $123 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiovascular | 2025 | |
| 2025-05-07 | scPharmaceuticals Inc. | $21 | Food and Beverage | In-kind items and services | FUROSCIX Drug, Cardiology | 2025 | |
| 2025-05-06 | Recor Medical Inc | $168 | Food and Beverage | Cash or cash equivalent | Paradise Ultrasound Renal Denervation System Device, Devices | 2025 | |
| 2025-04-30 | Novo Nordisk Inc | $122 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-04-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-04-30 | Amgen Inc. | $5 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiovascular | 2025 | |
| 2025-04-29 | Eli Lilly and Company | $2,706 | Research payment | In-kind items and services | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AN | 2025 | |
| 2025-04-29 | Actelion Pharmaceuticals US, Inc. | $33 | Food and Beverage | In-kind items and services | OPSUMIT Drug, Cardiology | 2025 | |
| 2025-04-26 | Boston Scientific Corporation | $18 | Food and Beverage | In-kind items and services | WATCHMAN Access System Device, WATCHMAN_IC | 2025 | |
| 2025-04-25 | Novo Nordisk Inc | $1,962 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-04-25 | Recor Medical Inc | $27 | Food and Beverage | Cash or cash equivalent | Paradise Ultrasound Renal Denervation System Device, Devices | 2025 | |
| 2025-04-24 | AstraZeneca Pharmaceuticals LP | $32 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-04-24 | Merck Sharp & Dohme LLC | $20 | Food and Beverage | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | 2025 | |
| 2025-04-23 | Esperion Therapeutics, Inc. | $27 | Food and Beverage | In-kind items and services | NEXLETOL Drug, ANTILIPEMIC AGENTS | 2025 | |
| 2025-04-21 | Recor Medical Inc | $32 | Food and Beverage | Cash or cash equivalent | Paradise Ultrasound Renal Denervation System Device, Devices | 2025 | |
| 2025-04-18 | Abbott Laboratories | $21 | Food and Beverage | In-kind items and services | DRAGONFLY OPSTAR Device, Vascular | 2025 | |
| 2025-04-18 | scPharmaceuticals Inc. | $7 | Food and Beverage | In-kind items and services | FUROSCIX Drug, Cardiology | 2025 | |
| 2025-04-15 | Novo Nordisk Inc | $118 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-04-09 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-04-09 | Novo Nordisk Inc | $0 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-04-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-04-04 | E.R. Squibb & Sons, L.L.C. | $17 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2025 | |
| 2025-04-02 | Amgen Inc. | $21 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiovascular | 2025 | |
| 2025-03-26 | Amgen Inc. | $2,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiovascular | 2025 | |
| 2025-03-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-03-20 | Merck Sharp & Dohme LLC | $18 | Food and Beverage | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | 2025 | |
| 2025-03-19 | Amgen Inc. | $121 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiovascular | 2025 | |
| 2025-03-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-03-12 | Amgen Inc. | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Repatha Biological, Cardiovascular | 2025 | |
| 2025-03-12 | Amgen Inc. | $700 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-03-12 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-03-06 | Actelion Pharmaceuticals US, Inc. | $22 | Food and Beverage | In-kind items and services | OPSUMIT Drug, Cardiology | 2025 | |
| 2025-03-05 | scPharmaceuticals Inc. | $19 | Food and Beverage | In-kind items and services | FUROSCIX Drug, Cardiology | 2025 | |
| 2025-03-01 | Daiichi Sankyo Inc. | $13 | Food and Beverage | In-kind items and services | INJECTAFER Drug, Iron Deficiency Anemia | 2025 | |
| 2025-02-26 | Novo Nordisk Inc | $5,102 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-02-26 | Boston Scientific Corporation | $139 | Food and Beverage | In-kind items and services | Wolverine Coronary Cutting Balloon Device, Wolverine Coronary Cutting Balloon_IC | 2025 | |
| 2025-02-26 | Novo Nordisk Inc | $121 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-02-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-02-19 | Novo Nordisk Inc | $5,102 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2025-02-19 | Novo Nordisk Inc | $119 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-02-13 | Merck Sharp & Dohme LLC | $18 | Food and Beverage | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | 2025 | |
| 2025-01-31 | Actelion Pharmaceuticals US, Inc. | $27 | Food and Beverage | In-kind items and services | OPSUMIT Drug, Cardiology | 2025 | |
| 2025-01-31 | Daiichi Sankyo Inc. | $14 | Food and Beverage | In-kind items and services | INJECTAFER Drug, Iron Deficiency Anemia | 2025 | |
| 2025-01-28 | PFIZER INC. | $20 | Food and Beverage | In-kind items and services | VYNDAQEL Drug, CARDIOVASCULAR | 2025 | |
| 2025-01-24 | Esperion Therapeutics, Inc. | $27 | Food and Beverage | In-kind items and services | NEXLETOL Drug, ANTILIPEMIC AGENTS | 2025 | |
| 2025-01-22 | Novartis Pharmaceuticals Corporation | $33 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-01-21 | CVRx, Inc. | $141 | Food and Beverage | Cash or cash equivalent | Barostim Neo System Device, Heart Failure and Hypertension | 2025 | |
| 2025-01-18 | Daiichi Sankyo Inc. | $15 | Food and Beverage | In-kind items and services | INJECTAFER Drug, Iron Deficiency Anemia | 2025 | |
| 2025-01-16 | Boston Scientific Corporation | $23 | Food and Beverage | In-kind items and services | WATCHMAN Access System Device, WATCHMAN_IC | 2025 | |
| 2025-01-15 | AstraZeneca Pharmaceuticals LP | $71 | Food and Beverage (10 payments) | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-01-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-01-10 | E.R. Squibb & Sons, L.L.C. | $17 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2025 | |
| 2025-01-08 | Esperion Therapeutics, Inc. | $9 | Food and Beverage | In-kind items and services | NEXLETOL Drug, ANTILIPEMIC AGENTS | 2025 | |
| 2025-01-01 | Novo Nordisk Inc | $2,001 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Wegovy Drug, Obesity | 2025 | |
| 2024-12-20 | Boston Scientific Corporation | $28 | Food and Beverage | In-kind items and services | WATCHMAN Access System Device, WATCHMAN_IC | 2024 | |
| 2024-12-19 | E.R. Squibb & Sons, L.L.C. | $17 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2024 | |
| 2024-12-11 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $16 | Food and Beverage | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2024 | |
| 2024-12-05 | Abbott Laboratories | $126 | Food and Beverage | In-kind items and services | AVEIR Device, Cardiac Rhythm Management | 2024 | |
| 2024-12-05 | Abbott Laboratories | $45 | Food and Beverage | In-kind items and services | AVEIR Device, Cardiac Rhythm Management | 2024 |
The latest 200 records of 1,468.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | Merck Sharp & Dohme LLC | Carient Heart & Vascular - Manassas | $9,108 | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2025 |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $3,699 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $400 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $434 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-12-03 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $53 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-10-31 | Ionis Pharmaceuticals, Inc. | Carient Heart and Vascular | $400 | IS354CS9 | 2025 |
| 2025-10-29 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $3,240 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-10-28 | Eli Lilly and Company | CARIENT HEART AND VASCULAR_MANASSAS | $65,121 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF MUVALAPLIN ON THE REDUCTION O | 2025 |
| 2025-10-14 | Ionis Pharmaceuticals, Inc. | Carient Heart and Vascular | $1,600 | IS354CS9 | 2025 |
| 2025-10-14 | Ionis Pharmaceuticals, Inc. | Carient Heart and Vascular | $340 | IS354CS9 | 2025 |
| 2025-10-14 | Ionis Pharmaceuticals, Inc. | Carient Heart and Vascular | $22,155 | IS354CS9 | 2025 |
| 2025-10-14 | Ionis Pharmaceuticals, Inc. | Carient Heart and Vascular | $2,500 | IS354CS9 | 2025 |
| 2025-10-01 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $400 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-10-01 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $738 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-09-24 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $1,200 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-09-24 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $3,400 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-09-24 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $53 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-09-08 | Organon Llc | Carient Heart and Vascular | $1,685 | 1242-035 | 2025 |
| 2025-09-08 | Merck Sharp & Dohme LLC | Carient Heart & Vascular - Manassas | $20,130 | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2025 |
| 2025-08-13 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $117 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-08-13 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $159 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-08-13 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $400 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-08-06 | Ionis Pharmaceuticals, Inc. | Carient Heart and Vascular | $6,727 | IS354CS9 | 2025 |
| 2025-07-18 | Ionis Pharmaceuticals, Inc. | Carient Heart and Vascular | $5,288 | IS354CS9 | 2025 |
| 2025-07-18 | Ionis Pharmaceuticals, Inc. | Carient Heart and Vascular | $500 | IS354CS9 | 2025 |
| 2025-07-18 | Ionis Pharmaceuticals, Inc. | Carient Heart and Vascular | $700 | IS354CS9 | 2025 |
| 2025-07-18 | Ionis Pharmaceuticals, Inc. | Carient Heart and Vascular | $800 | IS354CS9 | 2025 |
| 2025-07-18 | Ionis Pharmaceuticals, Inc. | Carient Heart and Vascular | $44 | IS354CS9 | 2025 |
| 2025-07-18 | Ionis Pharmaceuticals, Inc. | Carient Heart and Vascular | $99 | IS354CS9 | 2025 |
| 2025-07-18 | Ionis Pharmaceuticals, Inc. | Carient Heart and Vascular | $256 | IS354CS9 | 2025 |
| 2025-07-16 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $5,785 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-07-09 | Eli Lilly and Company | CARIENT HEART AND VASCULAR_MANASSAS | $6,625 | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AN | 2025 |
| 2025-07-08 | Eli Lilly and Company | CARIENT HEART AND VASCULAR_MANASSAS | $210,437 | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AN | 2025 |
| 2025-06-25 | Ionis Pharmaceuticals, Inc. | Carient Heart and Vascular | $512 | IS354CS9 | 2025 |
| 2025-06-25 | Ionis Pharmaceuticals, Inc. | Carient Heart and Vascular | $10,576 | IS354CS9 | 2025 |
| 2025-06-25 | Ionis Pharmaceuticals, Inc. | Carient Heart and Vascular | $50 | IS354CS9 | 2025 |
| 2025-06-25 | Ionis Pharmaceuticals, Inc. | Carient Heart and Vascular | $5,288 | IS354CS9 | 2025 |
| 2025-06-25 | Ionis Pharmaceuticals, Inc. | Carient Heart and Vascular | $800 | IS354CS9 | 2025 |
| 2025-06-25 | Ionis Pharmaceuticals, Inc. | Carient Heart and Vascular | $750 | IS354CS9 | 2025 |
| 2025-06-25 | Ionis Pharmaceuticals, Inc. | Carient Heart and Vascular | $256 | IS354CS9 | 2025 |
| 2025-04-18 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $5,598 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-02-11 | Novartis Pharmaceuticals Corporation | CARIENT HEART VASCULAR | $57,484 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2025 |
| 2025-02-03 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $14,798 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-02-03 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $2,500 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-02-03 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $106 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-02-03 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $346 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-02-03 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $16,186 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-01-29 | AstraZeneca UK Limited | Carient Heart and Vascular | $161,873 | A Phase IIb Two cohort Randomised Placebo controlled Double blind Multicentre Dose ranging Study of AZD5462 in Stable Pa | 2025 |
| 2025-01-08 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $212 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-01-08 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $850 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-01-08 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $400 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2025 |
| 2025-01-06 | Novartis Pharmaceuticals Corporation | Carient Heart and Vascular | $144,094 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2025 |
| 2025-01-03 | Amgen Inc. | Carient Heart and Vascular | $145,744 | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascu | 2025 |
| 2025-01-03 | Novartis Pharmaceuticals Corporation | Carient Heart and Vascular | $646,610 | HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinica | 2025 |
| 2024-12-31 | Merck Sharp & Dohme LLC | Carient Heart & Vascular - Manassas | $4,398 | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | Carient Heart & Vascular - Manassas | $16,778 | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | Carient Heart & Vascular - Manassas | $13,739 | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2024 |
| 2024-10-04 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $1,500 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2024 |
| 2024-09-18 | Alnylam Pharmaceuticals Inc. | CARIENT HEART & VASCULAR, LLC | $15,000 | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St | 2024 |
| 2024-08-09 | AstraZeneca UK Limited | Carient Heart and Vascular | $59,799 | a phase IIb two cohort,randomised,placebo controlled,double blind,multi centre,dose ranging study of AZD5462 in stable p | 2024 |
| 2024-04-19 | Amgen Inc. | Carient Heart and Vascular | $95,526 | OCEANa-Outcomes P3 CV | 2024 |
| 2024-01-30 | Novartis Pharmaceuticals Corporation | CARIENT HEART VASCULAR | $262,430 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2024 |
| 2024-01-25 | Amgen Inc. | Carient Heart and Vascular | $14,614 | OCEANa-Outcomes P3 CV | 2024 |
| 2024-01-25 | Novartis Pharmaceuticals Corporation | Carient Heart and Vascular | $102,544 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2024 |
| 2024-01-04 | Boehringer Ingelheim International GmbH | Carient Heart And Vascular PC-Manassas | $8,071 | Empagliflozin for prevention of HHF and death after an AMI | 2024 |
| 2024-01-02 | Novartis Pharmaceuticals Corporation | Carient Heart and Vascular | $777,319 | HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinica | 2024 |
| 2023-12-31 | Merck Sharp & Dohme LLC | Carient Heart & Vascular - Manassas | $44,593 | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | Carient Heart & Vascular - Manassas | $5,568 | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | Carient Heart & Vascular - Manassas | $21,339 | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2023 |
| 2023-09-28 | Novartis Pharmaceuticals Corporation | CARIENT HEART & VASCULAR, LLC | $16,500 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2023 |
| 2023-08-24 | Novartis Pharmaceuticals Corporation | Carient Heart and Vascular | $6,500 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2023 |
| 2023-07-26 | Novartis Pharmaceuticals Corporation | Carient Heart and Vascular | $13,771 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2023 |
| 2023-05-09 | Novartis Pharmaceuticals Corporation | Carient Heart and Vascular | $264,951 | HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinica | 2023 |
| 2023-03-25 | Amgen Inc. | CARIENT HEART & VASCULAR, PC | $16,508 | Phase 3 - Cardiovascular Outcomes Trial | 2023 |
| 2023-02-24 | Amgen Inc. | CARIENT HEART & VASCULAR, PC | $17,180 | P0 ASCVD Olpasiran Prescreening for CVOT | 2023 |
| 2023-02-02 | Amgen Inc. | Carient Heart and Vascular | $22,046 | Phase 3 - Cardiovascular Outcomes Trial | 2023 |
| 2023-01-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | Carient Heart And Vascular PC-Manassas | $9,759 | Empagliflozin for prevention of HHF and death afte | 2023 |
| 2023-01-05 | Novartis Pharmaceuticals Corporation | Carient Heart and Vascular | $261,131 | HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinica | 2023 |
| 2023-01-03 | Boehringer Ingelheim International GmbH | Carient Heart And Vascular PC-Manassas | $16,291 | Empagliflozin for prevention of HHF and death afte | 2023 |
| 2022-12-31 | Merck Sharp & Dohme LLC | CARIENT HEART AND VASCULAR MANASSAS | $62,412 | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | CARIENT HEART AND VASCULAR MANASSAS | $1,960 | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | CARIENT HEART AND VASCULAR MANASSAS | $452 | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | CARIENT HEART AND VASCULAR MANASSAS | $10,405 | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2022 |
| 2022-01-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | Carient Heart And Vascular PC-Manassas | $48,795 | Empagliflozin for prevention of HHF and death afte | 2022 |
| 2022-01-10 | Novartis Pharmaceuticals Corporation | Carient Heart and Vascular | $354,833 | HPS-4/TIMI 65/ORION-4: A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL ASSESSING THE EFFECTS OF INCLISIRAN ON CLINICA | 2022 |
| 2022-01-04 | Boehringer Ingelheim International GmbH | Carient Heart And Vascular PC-Manassas | $36,481 | Empagliflozin for prevention of HHF and death afte | 2022 |
| 2021-12-31 | Merck Sharp & Dohme LLC | CARIENT HEART AND VASCULAR MANASSAS | $13,963 | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | CARIENT HEART AND VASCULAR MANASSAS | $1,910 | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2021 |
| 2021-12-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | Carient Heart And Vascular PC-Manassas | $6,506 | Empagliflozin for prevention of HHF and death after an AMI | 2021 |
| 2021-11-30 | Boehringer Ingelheim Pharma GmbH & Co.KG | Carient Heart And Vascular PC-Manassas | $6,506 | Empagliflozin for prevention of HHF and death after an AMI | 2021 |
| 2021-11-24 | Boehringer Ingelheim International GmbH | Carient Heart And Vascular PC-Manassas | $8,390 | Empagliflozin for prevention of HHF and death after an AMI | 2021 |
| 2021-11-01 | Boehringer Ingelheim International GmbH | Carient Heart And Vascular PC-Manassas | $2,284 | Empagliflozin for prevention of HHF and death after an AMI | 2021 |
| 2021-10-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | Carient Heart And Vascular PC-Manassas | $6,506 | Empagliflozin for prevention of HHF and death after an AMI | 2021 |
| 2021-08-18 | Boehringer Ingelheim International GmbH | Carient Heart And Vascular PC-Manassas | $3,822 | Empagliflozin for prevention of HHF and death after an AMI | 2021 |
| 2021-06-09 | Boehringer Ingelheim International GmbH | Carient Heart And Vascular PC-Manassas | $2,284 | Empagliflozin for prevention of HHF and death after an AMI | 2021 |
| 2021-04-27 | Abbott Laboratories | Inova Health Care Services | $450 | Abbott Vascular / XIENCE | 2021 |
| 2021-03-31 | Amgen Inc. | Carient Heart and Vascular | $275 | Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9i (cvMOBIUS) | 2021 |
| 2021-02-03 | Boehringer Ingelheim International GmbH | Carient Heart And Vascular PC-Manassas | $3,000 | Empagliflozin for prevention of HHF and death after an AMI | 2021 |
| 2021-01-31 | Boehringer Ingelheim Pharma GmbH & Co.KG | Carient Heart And Vascular PC-Manassas | $9,759 | Empagliflozin for prevention of HHF and death after an AMI | 2021 |
| 2021-01-27 | Novartis Pharmaceuticals Corporation | Carient Heart and Vascular | $300 | HPS-4/TIMI 65/ORION-4: A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL ASSESSING THE EFFECTS OF INCLISIRAN ON CLINICA | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Reston, VA, county Fairfax County, VA, state Virginia; placed by its city name.
| Measure | Place (city or town) Reston, VA | County Fairfax County, VA | State Virginia |
|---|---|---|---|
| Population B01003 | 64,414 | 1,147,837 | 8,705,170 |
| Population, 2020 census P1 | 63,226 | 1,150,309 | 8,631,393 |
| Median age B01002 | 40.1 | 39.1 | 39.0 |
| Under 18 B01001 | 18.6% | 22.9% | 21.7% |
| 65 and over B01001 | 16.2% | 15.0% | 16.7% |
| Households B11001 | 28,701 | 414,101 | 3,365,732 |
| Foreign born B05002 | 24.6% | 30.8% | 13.1% |
| Median household income B19013 | $148,710 | $153,637 | $93,170 |
| Median family income B19113 | $179,332 | $183,217 | $115,213 |
| Per capita income B19301 | $81,656 | $71,828 | $50,666 |
| Poverty rate B17001 | 5.7% | 5.9% | 9.9% |
| Unemployment rate B23025 | 5.0% | 4.2% | 4.3% |
| Civilian labor force B23025 | 39,566 | 637,207 | 4,468,236 |
| Mean commute (minutes) B08013 | 26.0 | 28.9 | 27.3 |
| Bachelor's degree or higher B15003 | 72.0% | 65.0% | 42.2% |
| Housing units B25001 | 30,485 | 430,047 | 3,684,756 |
| Owner-occupied B25003 | 60.6% | 68.6% | 67.3% |
| Renters B25003 | 39.4% | 31.4% | 32.7% |
| Median home value B25077 | $642,000 | $732,800 | $383,700 |
| Median gross rent B25064 | $2,231 | $2,276 | $1,579 |
| White, not Hispanic B03002 | 57.6% | 46.8% | 58.4% |
| Black B03002 | 7.9% | 9.4% | 18.3% |
| Hispanic or Latino B03002 | 16.4% | 17.6% | 11.0% |
| Asian B03002 | 10.9% | 19.9% | 6.9% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Reston, VA.
Comments